Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Drug

Mabwell’s Nectin-4 Targeting ADC 9MW2821 Shows Promise in Cervical Cancer Clinical Study

Fineline Cube Mar 18, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company

Everest Medicines Stakeholders Pledge Six-Month Hold Amid Confidence in Long-Term Growth

Fineline Cube Mar 18, 2024

Everest Medicines (HKG: 1952), a Chinese pharmaceutical firm, has received commitments from its controlling shareholder...

Company Drug

Novo Nordisk’s Wegovy Leads in Total US Prescriptions for Weight-Loss Market

Fineline Cube Mar 18, 2024

Novo Nordisk (CPH: NOVO-B), a leading pharmaceutical company, has seen its weight-loss drug Wegovy (semaglutide)...

Company Drug

FDA Advisory Committee Backs Wider Use of Abecma in Relapsed or Refractory Multiple Myeloma

Fineline Cube Mar 18, 2024

An advisory committee to the US Food and Drug Administration (FDA) has recommended the use...

Company Drug

Shanghai Henlius Initiates Phase I Trial for HLX42, an Innovative ADC Targeting EGFR

Fineline Cube Mar 15, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first subject dosing in a Phase...

Company Deals

AstraZeneca Acquires Amolyt Pharma for $800 Million to Bolster Rare Disease Pipeline

Fineline Cube Mar 15, 2024

AstraZeneca (AZ; NASDAQ: AZN) has finalized a definitive agreement to acquire France-based biopharmaceutical company Amolyt...

Company Drug

KeChow Pharma Secures Conditional Approval for HL-085, a First-of-Its-Kind MEK Inhibitor for Advanced Melanoma

Fineline Cube Mar 15, 2024

Shanghai-based KeChow Pharma has received conditional marketing approval from the National Medical Products Administration (NMPA)...

Company Deals

Boehringer Ingelheim, J&J, and Novo Holdings Invest in Asgard Therapeutics for Cancer Immunotherapy

Fineline Cube Mar 15, 2024

Germany’s Boehringer Ingelheim (BI), US-based Johnson & Johnson (J&J; NYSE: JNJ), and Denmark’s major Novo...

Company Drug

Pfizer’s Sugemalimab Secures NMPA Approval for Gastric and Gastroesophageal Junction Adenocarcinoma

Fineline Cube Mar 15, 2024

Pfizer (NYSE: PFE), a leading pharmaceutical company in the US, has announced that it has...

Company Drug

Madrigal Pharmaceuticals’ Rezdiffra Earns FDA Accelerated Approval for NASH in Adults

Fineline Cube Mar 15, 2024

The US Food and Drug Administration (FDA) has granted an accelerated approval to Madrigal Pharmaceuticals’...

Deals Hospital

Swire Pacific to Deepen Healthcare Investment Focus in China and Indonesia

Fineline Cube Mar 15, 2024

Swire Pacific, a Hong Kong-based conglomerate, is gearing up to focus on healthcare investments in...

Legal / IP

CNIPA Invalidates Novo Nordisk’s Victoza Patent, Opening Door for Chinese Biosimilars

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA) has declared invalid the patent No. 201510572124.1 held...

Drug Legal / IP

CNIPA Invalidates AbbVie Patents, Setting New Precedent for Pharmaceutical Disclosure

Fineline Cube Mar 14, 2024

The China National Intellectual Property Administration (CNIPA)’s Patent Re-examination Board (PRB) has reportedly invalidated two...

Company

BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries

Fineline Cube Mar 14, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...

Company

Innovent Biologics Denies Lab Closure, Confirms Relocation to California

Fineline Cube Mar 14, 2024

Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...

Company Deals

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

Fineline Cube Mar 14, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...

Company Legal / IP Policy / Regulatory

BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift

Fineline Cube Mar 14, 2024

The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...

Company Drug

European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use

Fineline Cube Mar 14, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...

Company Drug

Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations

Fineline Cube Mar 14, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...

Company Deals

Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development

Fineline Cube Mar 14, 2024

Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...

Posts pagination

1 … 392 393 394 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.